Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 15/20 | 0.88 |
| ▸ | TP53 | P04637 | 3/20 | 0.68 |
| ▸ | MAPT | P10636 | 3/20 | 0.67 |
| ▸ | RXFP1 | Q9HBX9 | 3/20 | 0.62 |
| ▸ | SLC14A1 | Q13336 | 1/20 | 0.62 |
| ▸ | POLB | P06746 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8029076 | 0.94 | HTR6 (1.00) | HTR6TP53MAPTRXFP1 | |
| SCHEMBL8028235 | 0.92 | HTR6 (0.89) | HTR6MAPTRXFP1 | |
| SCHEMBL8037799 | 0.90 | HTR6 (0.87) | HTR6TP53MAPTRXFP1POLB | |
| SCHEMBL8035052 | 0.90 | HTR6 (0.85) | HTR6TP53MAPTRXFP1 | |
| SCHEMBL8033357 | 0.88 | HTR6 (1.00) | HTR6MAPTRXFP1 | |
| SCHEMBL8019549 | 0.85 | HTR6 (1.00) | HTR6MAPTRXFP1 | |
| SCHEMBL15287921 | 0.82 | HTR6 (0.85) | HTR6TP53MAPTRXFP1SLC14A1 | |
| SCHEMBL15285592 | 0.82 | HTR6 (0.70) | HTR6TP53MAPTRXFP1SLC14A1 | |
| SCHEMBL8029679 | 0.81 | TP53 (1.00) | HTR6TP53MAPTRXFP1 | |
| SCHEMBL8028973 | 0.79 | HTR6 (0.73) | HTR6TP53MAPTRXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009093934-A2 | SUBSTITUTED 3-SULPHONYL-[1,2,3]TRIAZOLO [1,5-A]PYRIMIDINES-ANTAGONISTS OF SEROTONIN 5-HT6 RECEPTORS, MEDICINAL SUBSTANCE, PHARMACEUTICAL COMPOSITION, MEDICINAL PREPARATION AND METHODS FOR THE PRODUCTION THEREOF | ALLA CHEM, LLC (US) | 2009-07-30 | — | — | WO | disclosed |